Safety, Tolerability, and Pharmacokinetics of a Novel Anti-Influenza Agent ZX-7101A Tablets in Healthy Chinese Participants: A First-in-Human Phase I Clinical Study

•ZX-7101A is a novel cap-dependent endonuclease inhibitor.•A single dose of 40–320 mg ZX-7101A was safe and well-tolerated in healthy subjects.•A single oral dose of 40 mg and 80 mg was expected to exhibit adequate in vivo anti-influenza activity.•A high-fat meal decreased the exposure level of ZX-7...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	International journal of antimicrobial agents 2025-01, Vol.65 (1), p.107381, Article 107381
Hauptverfasser:	Wu, Junzhen, Wei, Qiong, Jin, Yi, Cao, Guoying, Yu, Jicheng, Wu, Xiaojie, Yang, Xinyi, Li, Yilin, Liu, Mei, Qin, Xiaoli, Ai, Jingwen, Wang, Yin, Zhang, Wenhong, Zhang, Jing
Format:	Artikel
Sprache:	eng
Schlagworte:	Cap-dependent endonuclease inhibitor Influenza Pharmacokinetics Safety ZX-7101 ZX-7101A tablets
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!